Zura Bio Ltd 8-K

What Happened

• On May 7, 2026, Zura Bio Limited filed an 8-K furnishing a press release that announced its first quarter 2026 financial results (Item 2.02). The press release is included as Exhibit 99.1 and is incorporated by reference.
• On the same date the company provided an updated corporate presentation for use at conferences and investor meetings; that presentation is filed as Exhibit 99.2 and is available via the “News & Events” section of investors.zurabio.com (Item 7.01). The report was signed by Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary.

Key Details

• Filing date: May 7, 2026 (Form 8-K, accession no. 0001628280-26-031701).
• Press release with Q1 2026 results furnished as Exhibit 99.1.
• Updated corporate presentation dated May 7, 2026 furnished as Exhibit 99.2 and posted on the company’s investor website.
• Report signed by Kim Davis in her roles as COO, Chief Legal Officer and Corporate Secretary.

Why It Matters

• The 8-K signals that Zura Bio has publicly reported its quarterly earnings and updated investor materials; investors should review Exhibit 99.1 for the specific quarterly revenue, net income/loss, cash position and any operational highlights.
• The updated corporate presentation (Exhibit 99.2) may contain refreshed strategy, pipeline or guidance-related slides that management will use in investor outreach — useful context for evaluating near-term expectations.
• These furnished documents are the authoritative sources for the quarter’s financial results and any related disclosures; check the exhibits and the company website for the full details.